ACUSPHERE, INC. |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2013 | Acusphere Appoints William Ramage as Chief Development Officer | CI |
| 2013 | Acusphere, Inc. has Changed its Ticker to ACUS from ACUSD | CI |
| Sales 2006 | 1.78 2.44 | Sales 2007 | 2.67 3.65 | Capitalization | 30.08M 41.19M |
|---|---|---|---|---|---|
| Net income 2006 | -61M -83.53M | Net income 2007 | -53M -72.58M | EV / Sales 2006 | 9,811,030 x |
| Net cash position 2006 | 52.87M 72.41M | Net cash position 2007 | 14.76M 20.21M | EV / Sales 2007 | 5,744,305 x |
| P/E ratio 2006 |
-1.06
x | P/E ratio 2007 |
-0.49
x | Employees | - |
| Yield 2006 * |
-
| Yield 2007 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Corporate Officer/Principal | - | 13-11-05 |
Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +16.50% | 42.12B | |
| +20.78% | 21.72B | |
| +21.14% | 15.75B | |
| +23.69% | 14.89B | |
| +57.44% | 13.06B | |
| -0.05% | 6.79B | |
| -14.94% | 6.3B | |
| +20.03% | 6.05B | |
| -8.87% | 5.73B |
